OUR FUNDING focus
1.1. Integrating accurate non-invasive surveillance methods, technologies and/or biomarkers for recipient care strategies
and EARLY identification of the onset of acute cellular rejection (ACR), antibody-mediated rejection (AMR) and/or
cardiac allograft vasculopathy (CAV).
1.2. Developing improved therapeutics and/or therapeutic strategies for acute cellular rejection (ACR), antibody-mediated
rejection (AMR) and/or cardiac allograft vasculopathy (CAV).
1.3. Developing novel immunotherapies, identification of novel targets for immunosuppression, improving methods for
monitoring and determining the optimal level of immunosuppression to prevent ACR, AMR, and/or CAV while
reducing/eliminating secondary conditions that may arise due to immunosuppression (e.g., renal; infectious).
1.4. Developing and validating experimental models to study the underlying mechanisms, therapies, and/or prevention of
1.5. Developing more evidence-based person-centered post-transplant care guidelines, including nutrition and exercise
2.1. Improving transitioning from pediatric to adult care/medication adherence.
2.2. Development of evidence-based tools for improving pediatric heart recipient and family education related to heart
2.3. Improving evidence-based diverse psycho-social support methods including technologies, hosted peer action groups,
virtual visit models and remote metrics.
3.1. Applying advanced data analytics to better integrate extracardiac and cardiovascular candidate risk factors including
degree of multiorgan dysfunction and frailty, race and ethnic group, and HLA and non-HLA sensitization.
3.2. Innovative strategies that would improve organ availability, matching, utilization, and allocation.
3.3. Pre-transplant modifications in donor heart immunogenicity.
3.4. Promotion of evidence-based optimization and standardization of pre-transplant protocols including donor selection and
3.5. Pediatric scaled xenotransplantation and/or tissue engineering.
Additional weighting is afforded to the impact of a proposed research study as evidenced by its potential to translate within the next five years; directly involving pediatric heart transplant
recipients and/or their families; and its potential to promote equity as well as standardization of post-transplant care of pediatric heart recipients.
- Please send questions to: Grants@enduringhearts.org
LOI Submission Deadline: April 22, 2023
Full Grant Proposal: May 15, 2023
Enduring Hearts partners with ISHLT to fully fund a transplant longevity award every two years. The purpose of the Award is to further the scientific understanding of the determinants of pediatric transplant heart longevity and thereby improve the quality and duration of life. The awardee will be announced at the ISHLT conference in Denver, Colorado in April 2023.
No Longer Accepting Applications
The organizational goal of Enduring Hearts is to promote research to improve longevity of, and quality of life for, pediatric heart transplant recipients, and ultimately reduce and eliminate pediatric heart disease. To date, Enduring Hearts has funded 1 to 2-year investigator-originated research projects consistent with these goals and below identified areas of scientific interest. Investigators must hold a PhD, MD, DNP or BSN and have an appointment with a Pediatric Heart Transplant Center or University. It is the expressed intent of Enduring Hearts to form collaborations with PHTS to achieve mutually shared goals.
The purpose of the collaboration is to further the scientific understanding of the determinants of longevity of transplanted pediatric recipients and their transplanted heart to improve the quality and duration of life.
2023 Application Submission Dates:
October 1, 2023 – October 31, 2023
2022 award Recipients
University of Florida
Abstract: Use Of Donor Hearts With Low Ejection Fraction In Pediatric Heart Transplantation: A PHTS Analysis (ISHLT 2022)
Irene Lytrivi, MD
Columbia University – Morgan Stanley Children’s Hospital of New York Presbyterian (CPM)
Abstract: Contemporary outcomes and management strategies of pediatric cardiac transplantation with a positive retrospective HLA crossmatch (AHA 2022)
Madeleine Townsend, MD
University of Alberta (UOA)
Abstract: Statin Use in Pediatric Heart Transplantation Recipients in the Current Era (ISHLT 2023)
ENDURING HEARTS Partners with AHA to fund pediatric heart Transplant research
We are excited to announce the first two awardees of the $3M joint research collaboration between Enduring Hearts and AHA.
Dr. Christopher Almond, Dr. Kevin Daly and Meghna Patel for receiving funding for “Clinical Ancillary Study to the TEAMMATE trial”
Dr. James Martin, Dr. Diwakar Turaga, and Dr.Iki Adachi on the selection of their study “Early Detection of Cardiac Allograft Vasculopathy in Post-Transplant Hearts via Single-Cell Genomics”